Inside CKD: Cost-Effectiveness of Multinational Screening for CKD
CKD screening may be cost-effective in general populations worldwide, including in populations aged ≥ 45 years. Our analysis corroborates global guideline recommendations for simultaneous eGFR and UACR testing if considered in the context of local factors.
Authors
- Timothy Coker (ORCID: https://orcid.org/0000-0002-2516-0639)
- Christian Fynbo Christiansen (ORCID: https://orcid.org/0000-0002-0727-953X)
- Jason Chon Jun Choo (ORCID: https://orcid.org/0000-0002-8477-0875)
- Salvatore Barone
- Gil Chernin (ORCID: https://orcid.org/0000-0001-7514-156X)
- Michel Jadoul (ORCID: https://orcid.org/0000-0001-7369-7812)
- Juan José García Sánchez (ORCID: https://orcid.org/0000-0001-6546-7769)
- Johan Ärnlöv (ORCID: https://orcid.org/0000-0002-6933-4637)
- Lise Retat (ORCID: https://orcid.org/0000-0002-6689-3599)
- Kook‐Hwan Oh (ORCID: https://orcid.org/0000-0001-9525-2179)
- Joshua Card-Gowers (ORCID: https://orcid.org/0000-0002-9928-8862)
- Navdeep Tangri (ORCID: https://orcid.org/0000-0002-5075-6370)
- Marcelo Costa Batista (ORCID: https://orcid.org/0000-0002-1399-0969)
- Stephen Nolan
Institutions
- AstraZeneca (United Kingdom) (GB)
- Cliniques Universitaires Saint-Luc (BE)
- Seoul National University (KR)
- Singapore General Hospital (SG)
- Kaplan Medical Center (IL)
- Hospital Israelita Albert Einstein (BR)
- Aarhus University Hospital (DK)
- Karolinska Institutet (SE)
- AstraZeneca (United States) (US)
- University of Manitoba (CA)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2025.01.020
- Citations
- 5
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 7.15